Figures & data
Figure 1. A (baseline): clinical aspect and dermoscopy (insert) of AA universalis; B (three months): regrowth (circles) under baricitinib treatment (4 mg/day); C (five months): relapse within the regrowth areas (circles) while under baricitinib (Phenotype 1); localized new areas of regrowth were observed (arrows).
Figure 2. A (baseline): clinical aspect and dermoscopy (insert) of severe AA (SALT = 70); B (three months): relapse within a previously unaffected area (circle) while under baricitinib treatment (4 mg/day) (Phenotype 2).
Figure 3. A (baseline): clinical aspect and dermoscopy (insert) of severe AA (SALT = 90); B (five months): regrowth under baricitinib treatment (4 mg/day); C (six months): relapse within the regrowth area (circle) while under baricitinib (Phenotype 1).
